Sandoz to commercialise opioid induced constipation tablet in EUAs it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi Share XSandoz to commercialise opioid induced constipation tablet in EUhttps://pharmaphorum.com/news/sandoz-to-commercialise-opioid-induced-constipation-tablet-in-eu/
CEO of Novartis’ generics unit quits, sparking sale speculationRichard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of Share XCEO of Novartis’ generics unit quits, sparking sale speculationhttps://pharmaphorum.com/news/ceo-of-sandoz-unit-quits-sparking-speculation-over-sale/
Sandoz announces results of digital innovation ‘HACk’A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic Share XSandoz announces results of digital innovation ‘HACk’https://pharmaphorum.com/news/sandoz-announces-results-of-digital-innovation-hack/
Sandoz selects finalists in digital tech healthcare access competitionSandoz has selected three finalists in a competition to use digital technology to increase access to medicines in Share XSandoz selects finalists in digital tech healthcare access competitionhttps://pharmaphorum.com/news/sandoz-selects-finalists-in-digital-tech-healthcare-access-competition/
Sandoz joins medical cannabis drive with Tilray dealNovartis’ Sandoz subsidiary has taken its first steps into the emerging market for medical cannabis products, signing a Share XSandoz joins medical cannabis drive with Tilray dealhttps://pharmaphorum.com/news/sandoz-joins-medical-cannabis-drive-with-tilray-deal/
FDA clears Pear/Sandoz app for opioid use disorderA second mobile app developed by Pear Therapeutics to help opioid use disorder patients who have a more Share XFDA clears Pear/Sandoz app for opioid use disorderhttps://pharmaphorum.com/news/fda-clears-pear-sandoz-app-for-opioid-use-disorder/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
Sandoz axes filing of US Rituxan biosimilarSandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved Share XSandoz axes filing of US Rituxan biosimilarhttps://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/
Billions up for grabs as EU patent on AbbVie’s Humira expiresThe patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a Share XBillions up for grabs as EU patent on AbbVie’s Humira expireshttps://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/
